GlassScriptPhysician profile
Aman S Gill
NPI 1497986525
$6,066.18
in general payments reported to CMS, 2019-2025
45 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $576 · 2021: $520 · 2022: $790 · 2023: $952 · 2024: $632 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,944.25 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,085.73 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $500.68 | 2019-2025 | Austedo Xr, Ajovy |
| Celgene Corporation | $474.26 | 2020-2025 | Zeposia |
| Ucb, INC. | $378.98 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Pfizer INC. | $347.54 | 2023-2024 | |
| Biogen, INC. | $308.15 | 2019-2025 | Vumerity, Tysabri |
| Amgen INC. | $289.92 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $251.51 | 2025 | |
| Genentech USA, INC. | $251.40 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Genzyme Corporation | $211.27 | 2019-2025 | |
| Allergan, INC. | $194.38 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $168.28 | 2020-2025 | Ingrezza, Ongentys |
| Vanda Pharmaceuticals INC. | $156.85 | 2025 | Ponvory |
| Novartis Pharmaceuticals Corporation | $140.82 | 2019-2024 | |
| Lilly USA, LLC | $134.09 | 2019-2023 | Emgality, Reyvow |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.